Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial.
Julien MazieresFabrice BarlesiIsabelle RouquetteOlivier MolinierBenjamin BesseIsabelle MonnetClarisse Audigier-ValetteAnne-Claire ToffartPatrick Aldo RenaultSéverine FrabouletSandrine HiretBertrand MennecierDidier DebieuvreVirginie WesteelPhilippe MassonAnne Madroszyk-FlandinEric PichonAlexis B CortotElodie AmourFranck MorinGérard ZalcmanDenis Moro-SibilotPierre-Jean SouquetPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Adding fulvestrant to EGFR-TKI is feasible, but not associated with prolonged PFS regardless of EGFR status. The lack of benefits while combining fulvestrant to EGFR-TKI does not support its future development in an unselected population.